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When a person is infected with malaria by the bite of a mosquito, sporozoites
travel through the bloodstream and enterhepatocytes . The parasite develops within
the liver cell for days to weeks, and during this period there are no symptoms. Only
after the liver stage parasitesmature, and merozoites arereleased to invade red blood
cells, do the fevers, chills andlethal complicationsofmalaria begin . Thus, a vaccine
aimed at sporozoites or liver stage parasites could eliminate malaria infections be-
fore clinical disease appears .
Immunization with radiation-attenuated sporozoites can protect rodents and
humans against live sporozoite challenge (1, 2) . One hypothesis is that this protec-
tive immunity is mediated by cytotoxic T cells directed against malaria antigens
on the infected hepatocyte . Several recently published experiments give support to
this idea . Immune animals became susceptible to sporozoite infection if they were
depleted of theirCD8+ T cells (3, 4), but the antigens recognized by these cells and
their site and mode of action were not determined. Infiltrates with CD8+ and CD4'
T cellsand other cellular elements were found in the livers ofimmune animals after
challenge with sporozoites and these infiltrates formed after the transfer ofimmune
CD8 + cells (5). Unfractionated spleen cells from immune animals eliminated
malaria-infected hepatocytes from in vitro culture (5), but the active cell types and
the targeted parasite antigens were not identified . A very recent study showed that
mice were protected by adoptive transfer of cloned CD8+T cells specific foran epi-
tope on the Plasmodium berghei circumsporozoite (CS) 1 protein (6) . However, it was
not shown that these cells were attacking infected hepatocytes directly, or releasing
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systemic mediators. We now show that a small peptide fragment of the Plasmodium
yoelii CS protein is a target of immune CD8 + cytotoxic T cells, and that these T
cells can kill cultured liver stage parasites in an antigen-specific and MHC-restricted
manner.
Materials and Methods
Mice.
￿
6-wk-old BALB/cByj and B10.D2 female mice were purchased from TheJackson
Laboratories, Bar Harbor, ME. BALB.K mice were obtained from Biocon, Rockville, MD.
Parasites.
￿
Clone 1.1 of P. yoelii 17X (NL) was grown in Anopheles stephensi mosquitos and
harvested as previously described (4). For some control experiments P. berghei ANKA clone
sporozoites were similarly grown and harvested.
Immunization Protocol.
￿
Dissected sporozoites received 12,000 Rad of 'y radiation from a
Cesium-137 source. Mice were given sporozoite immunizations through the tail vein at 2-4-
wk intervals. Either oftwo immunization schedules was used: two doses of60,000 and 50,000
sporozoites, or three doses of 75,000, 25,000, and 25,000 sporozoites. BALB/c mice were
protected against sporozoite challenge by either protocol.
Cell Culture.
￿
Spleens were removed from animals 2-12 wk after their last sporozoite im-
munization. 5 x 106 spleen cells were aliquoted into 2 ml of medium in wells of a 24-well
tissue culture plate. Medium was RPMI 1640 supplemented with 10% FCS, L-glutamine,
50 U/ml each of penicillin and streptomycin, and 2-ME at 5 x 10-5 M. Peptide antigens
were added at 5 fM concentrations, and cultures were incubated for 2 d at 37°C, 5% C02.
At that time, 0.2 ml of rat Con A culture supernatant (RCAS) (Collaborative Research Inc.,
Bedford, MA) was added to each well, and cultures were reincubated for an additional 5 d.
Peptides.
￿
Using the method of Houghten (7), peptides were synthesized corresponding
to amino acid sequences from the P . yoelii CS protein (8). Peptides were not desalted before
use and were not toxic to target cells or cell cultures at concentrations below 60 'M. They
were checked for purity by HPLC analysis. The 26 peptides used for initial screening spanned
the entire protein, each peptide being 20 amino acids long and overlapping its neighbors
by 10 amino acids (Fig. 1). For finer analysis of the CTL epitope, a nested set of peptides
was synthesized by progressively shortening the amino acid sequence 280-296 at both NH2
and COOH ends.
Monoclonal Antibodies.
￿
Anti-CD8 mAb 2.43 (9) was used for in vitro complement lysis.
For detection of liver stage schizonts, mAbs NYLS1 and NBSI were developed and kindly
provided by Dr. Yupin Charoenvit (Naval Medical Research Institute, Bethesda, MD).
Target Cells.
￿
Mouse tumor cell lines P815 (H-2d) and EL4 (H-2b) were purchased from
American Type Culture Collection, Rockville, MD. 18 h before use as targets, 106 cells were
placed in 2 ml of medium in single wells of a 24-well tissue culture plate. To this was added
0.1 MCi of 5'Cr as a sterile sodium-chromate solution (Dupont-New England Nuclear, Inc.,
Boston, MA) and synthetic peptide at the desired concentration. These cells were incubated
overnight at 37°C, 5% C02 . In the morning they were washed twice, recultured in 1 ml
of medium for 1 h at 37°C, washed twice again, and counted for use as target cells. For some
experiments, peptide was not added the night before, but only during the chromium-release
assay.
Chromium-release Assay.
￿
5,000 target cells were placed in well ofa 96-well U-bottomed plate.
Effector cells and synthetic peptide were added at the desired concentrations. For lysis of
CD8' cells, effector cells were incubated for 1 h at 37°C with mAb 2.43 and rabbit comple-
ment (Accurate Scientific, Westbury, NY). Normal rat serum Ig and complement were used
as control. Total volume was 0.2 ml, and experimental wells were reproduced in triplicate.
Plates were centrifuged at 500 g for 2 min, and incubated for 6 h at 37°C, 5 1 70 C02. At that
time supernatants were harvested using the Skatron SCS system (Skatron, Inc., Sterling,
VA), and released "Cr was detected by scintillation counting. Maximum release was deter-
mined by lysing target cells with 10% SDS. Spontaneous release of "Cr was -20% ofmax-
imum release. Calculation of percent specific lysis = [(experimental release - spontaneous
release)/(maximum release - spontaneous release)] x 100 . Calculation of percent peptideP. ,- CS
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FIGURE 1. The structure of the P.
yoelii CS protein is shown on the top
line (8). It is 368 amino acidsin length,
with three regions of repeating se-
quences shown by the three types of
hatching. RI and RII show the con-
stant regions found in the CS protein
of all Plasmodia. The middle lines show
the locations of the 26 synthetic
peptides.
specific lysis = (percent specific lysis oftargets with peptide) - (percent specific lysis oftargets
without peptide).
In Vitro Killing ofPlasmodium-infected Hepatocytes.
￿
Mouse hepatocytes were prepared using
enzymatic perfusion (10, 11). The hepatocyte preparations used in screening cultures were
depleted of Kupffer cells and macrophages by differential centrifugation and by cultivation
in medium containing 7 x 10-5 M hydrocortisone hemisuccinate. 105 hepatocytes were
seeded in eight-chamber plastic Lab-tek slides (Miles Research, Elkhart, IN) in MEM sup-
plemented with 10% FCS and allowed to attach overnight at 37°C, 5% C02 . After removal
of medium from the culture chambers, 5 x 104 sporozoites were added in 50 j1 of fresh
medium. 3 h after inoculation, medium containing the suspended sporozoites was removed
and replaced by 300,ul offreshmedium, and cultures were incubated for another 24 h. Medium
was then replaced by medium containing the required number ofcultured lymphocytes and
incubated overnight. Experimental wells were repeated in triplicate. Cultures were then ex-
amined by an immunofluorescence assay to determine the numbers ofsporozoites developing
into schizonts (12). P. yoelii schizonts were detected usingmAb NYLS1 specific for liver stage
schizonts, and P . berghei schizonts were detected using mAb NBS1 specific for P . berghei CS
protein. Inhibition was calculated by a pairwise comparison ofkilling by identically cultured
spleen cells from sporozoite immunized and normal mice. Percent inhibition = [1 - (number
of schizonts with lymphocytes cultured from immunized mice/number of schizonts with lym-
phocytes cultured from normal mice)] x 100.
Results
To look for CTL epitopes on the P. yoelii CS protein, we synthesized 26 peptides
that spanned the molecule (Fig. 1). We pooled these peptides into five groups, (1-6,
7-11, 12-16, 17-21, 22-26) and cultured spleen cells from sporozoite-immunized mice
with these pools and RCAS as a source of IL-2. After 7 d viable cells from these
cultures were used as effector cells in an in vitro cytotoxicity assay. The target cells
were "Cr-labeled syngeneic tumor cells pulsed with a single 1 of the 26 peptides.
Spleen cells that had been cultured with each peptide pool were then added to targets
pulsed with individual peptides from that pool. Peptide 19 (281-300), and to a lesser
degree peptide 18 (271-290), could sensitize target cells for lysis (Fig. 2).
When immune spleen cells from BALB/c mice were cultured with peptide 18 alone,
no CTL activity could be seen (data not shown). However cultures with peptide
19 as stimulating antigen produced CTL activity (Fig. 3). Both peptide 19 and RCAS
were necessary to generate this activity, which was MHC restricted, as peptide-pulsed
EL-4 cells (H-2b) were not lysed (Fig. 3, Exp. 1). Another strain of mice also car-
rying the H-2d alleles, B10.D2, also made CTL against peptide 19 when immunized
with P. yoelii sporozoites (data not shown). Spleen cells from unimmunized BALB/c
mice would not produce CTL when cultured with peptide 19 (Fig. 3, Exp. 2). Nei-
ther would peptide 19 stimulate CTL from mice immunized with P. berghei sporozoites766 CYTOTOXIC T CELL RECOGNITION OF CIRCUMSPOROZOITE PROTEIN
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(Fig. 3, Exp. 2). Therefore, the CTL do not represent an in vitro primary response
to peptide. Interestingly, the homologous region to peptide 19 in P. berghei(13) con-
tains two amino acid changes(Fig. 4), andasyngeneicpeptide with these twosubsti-
tutions could not label target cells for lysis by CTL reactive with peptide 19 (data
not shown). Lysis oftarget cells was mediated by CD8+ T cells as pretreatment of
cell cultures with anti-CD8 mAb and complement eliminated CTL activity (Fig.
3, Exp. 3). Thus, the CTL activity was from CD8+ cells that were MHC restricted,
and were highly specific to P. yoelii.
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FIGURE 2.
￿
Screeningpeptides
for CTL activity. Spleen cells
from sporozoite-immunized
BALB/c mice were cultured
with groups of synthetic pep-
tides (1-6, 7-11, 12-16, 17-21, or
22-26) andused as effector cells
in a 6-h 51Cr-release assay.
Targets were P815 cells pulsed
overnight with a single one of
the syntheticpeptides at a 5AM
concentration. E/Tratios were
40:1 .
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FIGURE 3.
￿
The specificity ofreaction with peptide 19. In Exp. 1, spleen cellsfrom immunized
BALB/c mice were cultured with or without the addition of peptide 19 at 5 AM concentration.
Target cells were either P815 cells without peptide, P815 cellspulsed with 5 AM peptide 19, or
EL-4 (H-26) mousetumorcellspulsed with 5 AM peptide 19. In Exp. 2, spleen cells from normal
mice, and mice immunized with P. yoelii or P. berghei sporozoites, were cultured with peptide 19
at 5 AM concentration. Target cells were P815 cells with or without pulsing with peptide 19. In
Exp. 3, spleen cells from immunizedmice were cultured with peptide 19 andtreated with anti-
CD8 mAbandcomplement before addition to target cells at an E/Tratioof40:1 . Controls were
treated with normal rat serum Ig and complement.
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To further define this CTL epitope, we synthesized a nested set of peptides by
deleting single amino acids from the NH2 and COOH ends of the P . yoelii CS
280-300 sequence. Immune spleen cells cultured with peptide 19 (281-300) were
then tested against tumortargets pulsed with thenested peptides at various concen-
trations (Fig. 5). Shortening or lengthening by a single NH2-terminal amino acid
reduced target cell labeling, and shortening by two amino acids abolished all lysis.
At the COOH terminus, truncated peptides had full activity until the isoleucine
at position 296 was removed. Complete loss of target sensitization occurred with
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￿
The upperline showsthe
sequence from aminoacid 281-296of
theP.yoeliiCS gene(8), whichwe have
called PYCTLI. Thesecond line shows
theP. berghei CS aminoacid sequence
(13) with thetwodifferences indicated
by asterisks. Theboxcontains thecore
sequence of PYCTLI defined by ex-
periments in Fig. 5.
FIGURE 5. Fine mapping of
theCTLepitope ofpeptide 19.
Spleen cellsfrom sporozoite im-
munized BALB/c mice were
cultured with peptide 19 (amino
acids281-300) andthen tested
in aCTL assayagainst targets
in the presence of each of the
nested peptides at several con-
centrations.
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deletion ofthe lysine at position 294. Thus a 13-amino acid core seemsto be essen-
tial for sensitization but optimal activity requires a peptide containing one addi-
tional N112-terminal, and two additional C0011-terminal residues (Fig. 4). We
have named this 16-amino acid sequence PYCTLI.
Although infected hepatocytes can be killed by immune T cells (5), no malaria
antigens, including the CS protein, had been previously identified on the surface
ofinfected liver cells. We wished to know ifPYCTLI wasatarget antigenonmalaria-
infected hepatocytes. Mouse hepatocytes were cultured in monolayers and infected
with P. yoelii sporozoites (5, 10-12). 24 h later spleen cell cultures from sporozoite-
immunized or normal mice stimulated with PYCTLI ora control(peptide 15) were
added and allowed to remain overnight. The hepatocyte cultures were then fixed
and stained, and the number of liver stage malaria parasites was counted. Spleen
cell cultures stimulated with PYCTLI substantially decreased the number ofliver
stage parasites presentin the cultures (Fig. 6). This effect was not seen when control
peptide was used to stimulate cultures ofimmune spleen cells. Antiparasitic activity
wasMHC restricted, asparasites grown inBALB.K livercellswere not affected (Fig.
6). Theeffector cells were also antigen specific, as P. bergthei liver stage parasites were
not killed.
Discussion
Thesedatademonstrate that PYCTLI, a 16-amino acid fragment from theP .yoelii
CS protein, is a biologically significant epitope recognized by CTLon infectedliver
cells. Immunization with irradiated sporozoites induces CD8+, MHC-restricted
CTL to PYCTLI, and specific, MHC-restrictedCTLtothispeptideeliminate para-
sites from hepatocyte culture. PYCTLI is thus the first known malaria antigen
presented on the surface of infected hepatocytes. It may derive from CS protein
sloughed into the liver cell cytoplasm during sporozoite invasion (14-16), or repre-
sent material passing through the parasitophorous vacuole. In either case, ourdata
show that PYCTLI is presented with class I molecules on the hepatocyte surface.
100
80
60
40
20
0
0.5 0.25
Lymphocytes x 10'
Hepetocyte
Infecting Stimulating
spwozoite Peplide
B&INc P.yoehi
￿
PYCTLI
"
￿
BalWc P. yoelii
￿
Control
O
￿
Bell P.yoelii
￿
PYCTLI
Bab.K P.yoelu
￿
Control
" BNWc P.berghei PYCTL1
O
￿
Belb/c P.berghei Control
FIGURE 6. Inhibition of parasite
growth in hepatocytes. Hepatocytes
from BALB/c (H-2d) or BALB.K (H-
2k)mice werecultured in monolayers,
infected with P. yoelii or P. berghei
ANKA sporozoites, andincubatedfor
24 h. At that time, spleen cells from
normal BALB/c or P. yoelii sporozoite
immunized BALB/c mice cultured
with either PYCTLI or peptide 15
(control)were addedto theinfected he-
patocytes at several concentrations.
24 h later the hepatocyte monolayers
were fixedand stained, and the num-
bers ofliverstageparasiteswas count-
ed. Numbers of parasites in cultures
with immune and normal spleen cells
were compared, andpercentinhibition
wascalculated. Negative inhibition is
marked as zero.WEISS ET AL.
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PYCTLI appears to be the only class I-restricted CTL epitope on the P . yoelii
CS protein recognized by sporozoite-immunized H-2d mice. We have mapped a
13-amino acid minimal core required for sensitization oftargets forlysis, and 3 ad-
jacent amino acids that enhance activity to maximal levels. In our initial screening
experiments, a20-amino acidpeptide(281-300) containing this epitope was themost
effective ofall peptides at sensitizingtargetsforlysis. This peptide containing PYCTLI
was able to stimulate immune cells to become CTL in vitro, as well as to sensitize
targets for lysis by these cells. The neighboring peptide (271-290), containing 10
of the 13 core amino acids ofPYCTLI, had some reduced ability to label targets
in some experiments, but was unable to stimulate immune cells to have cytotoxic
activity. Therefore, we do not believe that this activity in peptide 271-290 of the
P. yoelii CS represents a separate epitope in BALB/c mice.
Synthetic peptides provided an easy means ofdefining this CTL epitope. There
are two complementary strategies for using peptides to find T cell epitopes. The
first is to synthesize peptides chosen bypredictive algorithms (17, 18). PYCTLI was
predicted to fold as an amphipathic a-helix, and was a T epitope candidate on that
basis. The second strategy is to empirically produce peptides that are screened for
reactivity with T cells. Typically, it is notpractical tosynthesizeall possible peptides,
and overlapping peptides are used. This works well ifT cell epitopes are as short
as eight or nine amino acids, but screening is difficult for longer T cell epitopes.
Ourseries ofoverlappingpeptides, 20 amino acidslongoverlappingby 10, reproduces
all possible sequences of 11 amino acids or shorter. However, we are missing 10%
ofall possible 12-amino acid sequences, and 20% ofall 13-amino acid sequences.
Our core sequence ofPYCTLI has 13 amino acids, and 16 amino acids are neces-
sary for optimal activity. By these calculations there is a small chance that another
long H-2d-restricted CTL epitope might exist on the P . yoelii CS protein, but this
seems unlikely as most T cell epitopes are shorter than 13 amino acids.
PYCTLI is distinct from, but overlaps by nine amino acids, the recently described
CTL epitope 249-260 on the P . berghei CS protein (NDDSYIPSAEKI) (6). Four
ofourexperimentsillustrate theirdifferences. First, theP . bergheipeptide corresponding
to PYCTLI (Fig. 4) cannot sensitize targets for killing byCTL to PYCTLI. Second,
epitope mappingexperimentsusingnested peptides (Fig. 5) show thatthe fourCOOH-
terminal amino acids ofPYCTLI are required for activity. These four are absent
from the P. bergheiepitope. Also, addition ofNH2-terminal amino acids to PYCTLI
decreases its ability to sensitize targets, although lengthening increases its overlap
with the P. berghei epitope. Third, spleen cells from BALB/c mice immunized with
P. berghei sporozoites could not be stimulated to make CTL to PYCTLI. Lastly, P .
berghei infected hepatocytes were not killed by PYCTLI reactive cultures that did
kill P .yoeliiliverstageparasites. Weconclude thatP .yoelii andP. bergheicontain different
epitopes mapping to a small region of the CS molecule.
This region, adjacent to the NH2 terminal ofconstant region II, may be a center
for T cell reactivity on all CS proteins. It is the site of TH2R, a dominant CD4
T cell epitope on the P . falciparum CS protein (19). In P. yoelii, P . berghei, and P . fal-
ciparum this region has the amino acid sequence consistent with folding as an am-
phipathica-helix(17). This mayreflect astructural requirement forthenormal func-
tionoftheCS protein on sporozoites, which incidentlymakes it a conspicuous target
antigen for T cells. In P . falciparum, naturally occurring variation at the Th2R site770 CYTOTOXIC T CELL RECOGNITION OF CIRCUMSPOROZOITE PROTEIN
showstheimportance ofselectivepressure directed at thisregion (20). Interestingly,
these variantsequencesofTH2Rcanstillberecognized byTcells ofdifferentspecificity
(21). The parasite appears unable to modify this part of the protein sufficiently to
destroy the structure recognized by T cells.
Avaccine that inducedCTL to the CS protein might be expected to protect mice
against malariaby killing infected livercells. However, there may be many obstacles
to this approach. Although CTL to PYCTL1 are induced by irradiated sporozoites
and are active against infected hepatocytes, it is quite possible that other non-CS
proteins in P . yoelii have CTL epitopes that are more prominent in the protective
immuneresponse. Wecannot be sure from these studies whether PYCTLI is a major
player inimmunity to sporozoitechallenge.Wehavefoundthat although both BALB/c
(H-2d) and1310.132 (H-2d) mice make CTL against PYCTL1 when immunizedwith
P, yoelii sporozoites, only the BALB/c mice are solidly protected against sporozoite
challenge (22). Also, both recombinant Salmonella andpseudorabies virus containing
the P. yoelii CS gene, successfully induced CTL to PYCTLI in BALB/c mice but
the animals were not protected against infection by sporozoites (Flynn, J., W. R.
Weiss, K. A. Norris, H. S. Seifert, S. Kumar, and M. So, manuscript in prepara-
tion). The CS protein may be a more important antigen in P . berghei. Recombinant
Salmonella containing the P . berghei CS can partially protect mice against P . berghei
sporozoites (23). As mentioned previously, CTL clones to the P. berghei CS can also
protectmice (6). We concludethat the CSproteinisamore significant antigen quan-
titatively or qualitatively in some malarias than in others. What determines this
remains unknown, as does its role in immunity to the human malarias.
Otherdifficulties cloud the path toward CTL-based vaccines against malaria. We
have found only a single CTL epitope recognized by H-2d mice on the P . yoelii CS
protein. Similarly, H-2d mice recognize only one CTL epitope on the P. berghei CS
protein(6). TheP .falciparumCSprotein contains asingle CTL epitope seenby H-2k
mice and no CTL epitopes seen by H-2d mice (24). This paucity ofCTL epitopes
has also been seen when other proteins have been analyzed (25-27), but it is not
understood why they are so much less frequent than T helper epitopes. An ideal
CTL vaccine would contain multiple parasite CTL epitopes, which will probably
need to be drawn from many parasite antigens which are at this point undefined.
This multiplicity wouldcircumvent thelack ofpresentation bycertain MHC alleles,
andparasite variationofT cellepitopes (20). Immunization withP . berghei-irradiated
sporozoitesprotects all strains ofmice, indicatingthat manysuch antigens may exist
(28). However, in the case ofP . yoelii, even immunization with the whole irradiated
sporozoite only protects a few strains ofcongenic mice (22). Ifthe human malarias
behave as P. yoelii instead ofP . berghei, any vaccine may have to do better than the
whole radiation-attenuated parasiteto overcome genetic low responsiveness tomalaria
antigens.
Some answers to these problems are on the horizon. T helper epitopes have been
found that are recognized by alarge number ofMHC alleles (29), and it is possible
thatwidely reactive CTL epitopes may exist as well. In addition, there is muchwork
currently aimed at defining other target antigens on infected liver cells besides the
CS protein (30, 31). It is our hope that the addition ofthese factors to T epitopes
from the CS protein will result in a vaccine that will overcome the limitations of
genetic control and parasite variation.Summary
Irradiated malaria sporozoites can induce CD8+ T cells that are required for pro-
tection against infection. However, the parasite antigens targeted by this immune
response are unknown. We have discovered a 16-amino acid epitope from the Plas-
modiumyoelii circumsporozoite (CS) protein that is recognized by cytotoxic T cells
from immune mice. Lymphocytes stimulated with this peptide can kill P . yoelii liver
stage parasites in vitro in an MHC-restricted, antigen-specific manner. Thus, epi-
topes from the CS protein are presented on the surface of infected hepatocytes and
can be targets for T cells, even though intact CS protein has not been detected on
the surface of the infected hepatocyte. A vaccine that induced CTL to parasite an-
tigens might protect humans against malaria by eliminating liver stage parasites.
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